Steven Hoerter
Chief Executive Officer at DECIPHERA PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 2024-05-30
Profile
Steven L.
Hoerter is currently the President, Director & Chief Executive Officer at Deciphera Pharmaceuticals LLC.
He is also the President, Chief Executive Officer & Director at Deciphera Pharmaceuticals, Inc. Additionally, he serves as an Independent Director at Oric Pharmaceuticals, Inc. Previously, Mr. Hoerter held positions as the Director-Pipeline Development at Genentech, Inc. from 2005 to 2010.
He was an Independent Director at Constellation Pharmaceuticals, Inc. from 2018 to 2021, and also served as an Independent Director at Constellation Pharmaceuticals, Inc. from 2016 to 2018.
He was an Independent Director at Ignyta, Inc. from 2016 to 2018.
From 2016 to 2019, he served as the Chief Commercial Officer at Agios Pharmaceuticals, Inc. .
Mr. Hoerter has also worked at Roche Group as the GM, Head-Sub-Saharan Africa & Indian Ocean Region.
He was the Chief Commercial Officer & Executive VP at Clovis Oncology, Inc. from 2015 to 2016.
In terms of education, Mr. Hoerter holds an MBA from the University of Tilburg, an undergraduate degree from Bucknell University, and a graduate degree from Purdue University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-03-30 | 72,763 ( 0.08% ) | 2 M $ | 2024-05-30 | |
ORIC PHARMACEUTICALS INC
-.--% | 2024-03-30 | 0 ( -.--% ) | - $ | 2024-05-30 |
Steven Hoerter active positions
Companies | Position | Start |
---|---|---|
DECIPHERA PHARMACEUTICALS, INC. | Chief Executive Officer | 2019-03-17 |
ORIC PHARMACEUTICALS, INC. | Director/Board Member | 2021-08-12 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Chief Executive Officer | 2019-02-28 |
Former positions of Steven Hoerter
Companies | Position | End |
---|---|---|
CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 2021-07-14 |
AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-02-28 |
IGNYTA INC | Director/Board Member | 2018-02-06 |
CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 2018-01-31 |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | 2016-01-31 |
Training of Steven Hoerter
Bucknell University | Undergraduate Degree |
University of Tilburg | Masters Business Admin |
Purdue University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
AGIOS PHARMACEUTICALS, INC. | Health Technology |
DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
ORIC PHARMACEUTICALS, INC. | Health Technology |
Private companies | 6 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Steven Hoerter